Drug Trial Radar · NCT03218917
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
256
Actual
Start
Oct 31, 2017
Primary completion
Dec 12, 2019
Study completion Dec 12, 2019
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
Conditions
- Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mgDrug
Administered once per day for 24 weeks
Brensocatib 25 mgDrug
Administered once per day for 24 weeks
PlaceboDrug
Administered once per day for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the First Pulmonary Exacerbation Over 24-Week Treatment PeriodTime frame: Baseline (Day 1) to Week 24
Locations
108 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Phoenix Medical Group
Peoria, Arizona
NewportNativeMD
Newport Beach, California
Palmtree Clinical Research
Palm Springs, California
UC Davis Medical Center
Sacramento, California
Stanford University Medical Center
Stanford, California
National Jewish Heath
Denver, Colorado
UConn Health Center
Farmington, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Clinical Research Specialists, LLC
Celebration, Florida
St. Francis Medical Institute
Clearwater, Florida
University of Florida
Gainesville, Florida
University of Miami Miller School of Medicine
Miami, Florida
San Marcus Research Clinic, Inc.
Miami Lakes, Florida
Sarasota Memorial Hospital Clinical Research Center
Sarasota, Florida
The Emory Clinic, Pulmonology
Atlanta, Georgia
University of Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
LSU Health Sciences Center
New Orleans, Louisiana
Johns Hopkins University, Division of Pulmonary and Critical Care Medicine
Baltimore, Maryland
Pulmonary and Critical Care Associates of Baltimore
Towson, Maryland
Mid Atlantic Pulmonary & Research Center
Westminster, Maryland
Michigan Medicine
Ann Arbor, Michigan
NYU Pulmonary & Critical Care Associates
New York, New York
Columbia University Medical Center/ New York Presbyterian Hospital
New York, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Novant Health Pulmonary Medicine South
Charlotte, North Carolina
Southeastern Research Center
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
SMS Clinical Research, LLC
Mesquite, Texas
The University of Texas Health Science at Tyler
Tyler, Texas
MultiCare Institute for Research & Innovation
Tacoma, Washington
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Mater Misericordia Medical Centre
Brisbane, Queensland, Australia
Gallipoli Medical Research Foundation
Brisbane, Queensland, Australia
Metro North Hospital and Health Service (The Prince Charles Hospital)
Chermside, Queensland, Australia
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.